Bino Pathiparampil, Head of Research at Elara Securities believes the broader pharma space is entering a more favourable phase as pricing concerns and regulatory worries ease while currency movements provide an additional boost.
Bino Pathiparampil, Head of Research at Elara Securities believes the broader pharma space is entering a more favourable phase as pricing concerns and regulatory worries ease while currency movements provide an additional boost.